Core Insights - CelLBxHealth presented a proof-of-concept study utilizing Roche Tissue Diagnostics' workflow at the 16th World ADC conference, highlighting its advancements in circulating tumor cell (CTC) intelligence [1] Company Summary - CelLBxHealth is recognized as a global leader in circulating tumor cell intelligence, showcasing its innovative capabilities in cancer diagnostics [1] - The company demonstrated the compatibility of its Parsortix platform with the Roche BenchMark ULTRA automated staining system, indicating potential for enhanced diagnostic workflows [1] Industry Context - The World ADC conference is noted as the largest global event dedicated to antibody-drug conjugates (ADCs), with over 1,400 attendees focused on advancing targeted cancer therapies, underscoring the significance of the event in the oncology field [1] - The study focused on three key drug targets: HER2 (breast cancer), TROP2 (lung cancer), and PSMA (prostate cancer), which are critical areas of research in targeted cancer therapies [1]